Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14660
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lawung R. | |
dc.contributor.author | Treeratanapiboon L. | |
dc.contributor.author | Prachayasittikul S. | |
dc.contributor.author | Prachayasittikul V. | |
dc.date.accessioned | 2021-04-05T03:36:18Z | - |
dc.date.available | 2021-04-05T03:36:18Z | - |
dc.date.issued | 2010 | |
dc.identifier.issn | 15701808 | |
dc.identifier.other | 2-s2.0-77958499309 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14660 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77958499309&doi=10.2174%2f157018010792929603&partnerID=40&md5=03dd7d646e3c50b31c359b7edba7555e | |
dc.description.abstract | In a previous study, 5-(1-adamantylthio)-3-picoline (I) and 3-(1-adamantylthio)-4-phenylpyridine (II) were shown to have potent antimicrobial activity. The present investigation is concerned with the antimicrobial action of thiopyridines I and II against methicillin-resistant Staphylococcus aureus (MRSA) isolates and with their murine fibroblast (L929) cytotoxicity. Thiopyridine II was found to display significant antimicrobial activity against all of the MRSA isolates tested, with minimum inhibitory concentrations (MIC) of 1-8 μg/mL. Moreover, both I and II attenuate the viability of L929 cells in a dose-dependent manner, displaying an IC50 of 68.4±6.0 and 47.3±5.6 μg/mL, respectively. These findings suggest that thiopyridine II is promising as a lead compound for further development as a therapeutic. © 2010 Bentham Science Publishers Ltd. | |
dc.subject | 3 (1 adamantylthio) 4 phenylpyridine | |
dc.subject | 5 (1 adamantylthio) 3 picoline | |
dc.subject | antibiotic agent | |
dc.subject | pyridine derivative | |
dc.subject | unclassified drug | |
dc.subject | animal cell | |
dc.subject | antibacterial activity | |
dc.subject | article | |
dc.subject | cell viability | |
dc.subject | controlled study | |
dc.subject | cytotoxicity | |
dc.subject | dose response | |
dc.subject | fibroblast | |
dc.subject | IC 50 | |
dc.subject | methicillin resistant Staphylococcus aureus | |
dc.subject | minimum inhibitory concentration | |
dc.subject | nonhuman | |
dc.subject | priority journal | |
dc.title | 3-(1-adamantylthio)-4-phenylpyridine as a potential therapeutic for methicillin-resistant staphylococcus aureus | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Letters in Drug Design and Discovery. Vol 7, No.9 (2010), p.674-678 | |
dc.identifier.doi | 10.2174/157018010792929603 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.